



# LTL-504 datasheet

<b>Origin</b>	Primary human ovarian cancer	<b>Histopathology</b>	High grade serous carcinoma
<b>Year of establishment</b>	2013	<b>Doubling time</b>	17-20 days (subrenal capsule grafting site)
<b>Local invasion</b>	No	<b>Metastasis</b>	No

The LTL-504 (Fig. 1) was developed from a patient's primary ovarian high grade serous carcinoma. Histopathologically, it closely resembles the patient's tumor (Fig. 2). When grafted under the renal capsules of SCID mice, the LTL-504 shows no local invasion or distant metastasis. The LTL-504 grows well subcutaneously. Viable tissues in early generations have been preserved following by cryopreservation (DMSO), and can be readily resurrected for grafting.



**Fig 1. H&E stained LTL-504 tissue sections.** A high grade serous adenocarcinoma grafted under the renal capsule of a NOD SCID mouse. The tumor cells grow in solid sheets, with histopathological characteristics similar to those of the original patient's cancer (Fig. 2). (200x)



**Fig. 2. Patient's cancer tissue before grafting.** The tumor is composed of highly pleomorphic cells and is extensively necrotic.

## Genetic and epigenetic characteristics

Tissue Microarrays containing LTL-504 tissues are in place for screening potential targets upon request.

## **Applications**

1. Pre-clinical evaluation of existing and potential anticancer drugs. Examination of drug efficacy on tumor growth, cell death (apoptosis, necrosis), tissue invasion, metastasis (in combination with metastatic tumor lines) and angiogenesis.
2. Discovery of potential therapeutic targets and/or biomarkers for drug sensitivity.
3. Study of mechanisms underlying tumor growth, progression and metastasis.

**For more information, please contact us by email: [LTL@bccrc.ca](mailto:LTL@bccrc.ca) or phone: (604) 675 8013**